Nuclear Medicine Market Expected to Reach $6.50 billion by 2026 - Bayer, Medtronic, General Electric, Cardinal Health, IBA, BWX Technologies

Nuclear Medicine is accounted for $3.50 billion in 2017 and is expected to reach $6.50 billion by 2026 growing at a CAGR of 7.1% during the forecast period. Factors such as growing demand for early & precise diagnostic methods, increasing incidence of cancer and cardiovascular disorders and huge demand for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging are driving the market growth. However, supply deficiency, reimbursement hurdles for the manufacturer and high capital investment are restricting the growth of the growth. Moreover, rising economies, upcoming radioisotopes and increasing usage across neurological applications are providing ample opportunities for the market growth.

Nuclear medicines are used for both diagnostic and therapeutic uses and there are more than 30 specific radiopharmaceuticals used by medical practitioners. Nuclear medicine comes under the field of molecular imaging, which occupy the use of very little amount of radioactive material to detect and treat disease Several forms of nuclear medicines are required in treating cancer, neurological disorders, gastrointestinal and other diseases.

Get Sample PDF For More Professional And Technical Insights at: https://www.premiummarketinsights.com/sample/SMRC00016625

On the basis of application, therapeutic segment witnessed steady growth due to the introduction of advanced protective measures and growing awareness regarding the therapeutic procedures. By geography, North America is dominating the market during the forecasting period owing to increasing aging population, technological advancements and the presence of favorable reimbursement policies in this region.

Some of the key players in the Nuclear Medicine Market include Bayer AG, Medtronic, plc, General Electric Co., Cardinal Health, Inc., IBA Group, BWX Technologies, Australian Nuclear Science & Technology Organization (ANSTO), Mallinckrodt plc., Eckert & Ziegler Group, Lantheus Medical Imaging, Inc., Jubilant Life Sciences, Eczacibasi-Monrol Nuclear Products, Curium, Bracco Imaging S.p.A and NTP Radioisotopes SOC Ltd.

Products Covered:
-Therapeutic
-Diagnostic

Applications Covered:
-Therapeutic Applications
-Diagnostic Applications

End Users Covered:
-Research institutes
-Hospitals and Diagnostic centers

What our report offers:
-Market share assessments for the regional and country level segments
-Market share analysis of the top industry players
-Strategic recommendations for the new entrants
-Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
-Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
-Strategic recommendations in key business segments based on the market estimations
-Competitive landscaping mapping the key common trends
-Company profiling with detailed strategies, financials, and recent developments
-Supply chain trends mapping the latest technological advancements

Get Complete Report at: https://www.premiummarketinsights.com/buy/SMRC00016625

Name: Sameer Joshi
Email: sales@premiummarketinsights.com
Organization: Premium Market Insights
Phone: +1-646-491-9876

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.

This release was published on openPR.